Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 microg/dl; range, 50-227 microg/dl) fell to the target range of <50 microg/dl (median, 42 microg/dl; range, 12-118 microg/dl) after two months. Penicillamine-induced hypocupremia was well tolerated for months. Drug-related myelosuppression, elevated liver function tests, and skin rash rapidly reversed with copper repletion. Median survival was 11.3 months, and progression-free survival was 7.1 months. Achievement of hypocupremia did not significantly increase survival. Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Cited by
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
Gupte, A., & Mumper, R. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.004 · Cited by 1,036
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Role of Copper on Mitochondrial Function and Metabolism
Ruiz, L. M., Libedinsky, A., & Elorza, A. A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.711227 · Cited by 564
Targeting cuproplasia and cuproptosis in cancer
Tang, D., Kroemer, G., & Kang, R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00876-0 · Cited by 443
COPPER AND ANGIOGENESIS: UNRAVELLING A RELATIONSHIP KEY TO CANCER PROGRESSION
Finney, L., Vogt, S., Fukai, T., & Glesne, D. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04969.x · Cited by 315
Metadata
- Authors
- Brem, S., Grossman, S. A., Carson, K. A., New, P., Phuphanich, S., Alavi, J. B., Mikkelsen, T., & Fisher, J. D.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-01
- Volume
- 7
- Issue
- 3
- Pages
- 246-253
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2046703630
- Cited by
- 132
- References
- 1
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. https://app.cochat.ai/papers/10.1215/s1152851704000869
- The paper
- Brem, S., Grossman, S. A., Carson, K. A., New, P., Phuphanich, S., Alavi, J. B., Mikkelsen, T., & Fisher, J. D. (2005). Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro-Oncology. https://doi.org/10.1215/s1152851704000869
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.